MicroRNA expression profile of bromocriptine-resistant prolactinomas
MicroRNA expression profile of bromocriptine-resistant prolactinomas
复制标题
溴隐亭耐药催乳素瘤的 MicroRNA 表达谱
DOI：
10.1016/j.mce.2014.07.014
复制
发表时间：
2014-09-05
影响因子：
4.1
通讯作者：
Zhao, Wei Guo
中科院分区：
文献类型：
--
作者：
Wu, Zhe Bao;Li, Wei Qiang;Zhao, Wei Guo
MicroRNA（miRNA）与肿瘤对化疗的耐药性有关。然而，关于溴隐亭耐药泌乳素瘤中miRNA的表达知之甚少。在这项研究中，23例泌乳素瘤样本被归类为溴隐亭敏感或耐药性根据溴隐亭耐药的临床定义，并使用Solexa测序确定其miRNA表达谱。我们发现41个miRNAs在两组之间差异表达，其中12个通过茎环qRT-PCR验证。与溴隐亭敏感性泌乳素瘤相比，溴隐亭耐药泌乳素瘤中hsa-mir-93、hsa-mir-17、hsa-mir-22*、hsa-mir-126*、hsa-mir-142- 3 p、hsa-mir-144*、hsa-mir-486- 5 p、hsa-mir-451和hsa-mir-92 a上调，hsa-mir-30 a、hsa-mir-382和hsa-mir-136下调。此外，沉默mir-93显著增加MMQ细胞对多巴胺激动剂处理的敏感性。Mir-93通过靶向3 '-UTR直接影响MMQ细胞中p21的表达。我们的研究是第一个确定与溴隐亭耐药催乳素瘤相关的miRNA表达谱。(C)2014爱思唯尔爱尔兰有限公司版权所有。
MicroRNAs (miRNA) have been implicated in the resistance of tumors to chemotherapy. However, little is known about miRNA expression in bromocriptine-resistant prolactinomas. In this study, 23 prolactinoma samples were classified as bromocriptine-sensitive or -resistant according to the clinical definition of bromocriptine resistance, and their miRNA expression profiles were determined using Solexa sequencing. We found 41 miRNAs that were differentially expressed between the two groups, and 12 of these were validated by stem-loop qRT-PCR. Hsa-mir-93, hsa-mir-17, hsa-mir-22*, hsa-mir-126*, hsa-mir-142-3p, hsa-mir-144*, hsa-mir-486-5p, hsa-mir-451, and hsa-mir-92a were up-regulated and hsa-mir-30a, hsa-mir-382, and hsa-mir-136 were down-regulated in bromocriptine-resistant prolactinomas in comparison with bromocriptine-sensitive prolactinomas. Furthermore, silencing of mir-93 significantly increased the sensitivity of MMQ cells to dopamine agonist treatment. Mir-93 directly affected p21 expression in MMQ cells by targeting the 3'-UTR. Our study is the first to identify a miRNA expression profile associated with bromocriptine-resistant prolactinoma. (C) 2014 Elsevier Ireland Ltd. All rights reserved.